Wockhardt is currently trading at Rs. 1317.80, up by 19.15 points or 1.47% from its previous closing of Rs. 1298.65 on the BSE.
The scrip opened at Rs. 1305.00 and has touched a high and low of Rs. 1325.00 and Rs. 1300.00 respectively. So far 30,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 1325.00 on 21-Aug-2012 and a 52 week low of Rs. 251.25 on 06-Jan-2012.
Last one week high and low of the scrip stood at Rs. 1325.00 and Rs. 1167.50 respectively. The current market cap of the company is Rs. 14,421.00 crore.
The promoters holding in the company stood at 73.64% while Institutions and Non-Institutions held 8.86% and 17.32% respectively.
Pharmaceutical and biotechnology major Wockhardt has received US Food and Drug Administration (USFDA) approval for marketing a generic version of 200mg tablets containing Entacapone, which is used in the treatment of Parkinson’s disease.
Entacapone tablet is the generic name for the brand Comtan, owned by Orion Corporation and marketed in the US by Novartis. Wockhardt will launch the product on September 30, 2012, with 180-days of exclusivity.
The incidence of Parkinson’s disease is increasing worldwide. According to IMS Health, the total market for this product in the US is about $98 million.
Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s , the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1861.70 |
Dr. Reddys Lab | 1389.35 |
Cipla | 1506.15 |
Lupin | 2228.00 |
Zydus Lifesciences | 972.70 |
View more.. |